Hippocampal vulnerability to hyperhomocysteinemia worsens pathological outcomes of mild traumatic brain injury in rats.
electron microscopy
neuronal cell death
oxidative stress
rat
traumatic brain injury
Journal
Journal of central nervous system disease
ISSN: 1179-5735
Titre abrégé: J Cent Nerv Syst Dis
Pays: United States
ID NLM: 101595026
Informations de publication
Date de publication:
2023
2023
Historique:
received:
22
06
2022
accepted:
09
02
2023
entrez:
13
3
2023
pubmed:
14
3
2023
medline:
14
3
2023
Statut:
epublish
Résumé
Mild traumatic brain injury (mTBI) generally resolves within weeks. However, 15-30% of patients present persistent pathological and neurobehavioral sequelae that negatively affect their quality of life. Hyperhomocysteinemia (HHCY) is a neurotoxic condition derived from homocysteine accumulation above 15 μM. HHCY can occur in diverse stressful situations, including those sustained by U.S. active-duty service members on the battlefield or during routine combat practice. Mild-TBI accounts for more than 80% of all TBI cases, and HHCY exists in 5-7% of the general population. We recently reported that moderate HHCY exacerbates mTBI-induced cortical injury pathophysiology, including increased oxidative stress. Several studies have demonstrated hippocampus vulnerability to oxidative stress and its downstream effects on inflammation and cell death. This study aimed to assess the deleterious impact of HHCY on mTBI-associated hippocampal pathological changes. We tested the hypothesis that moderate HHCY aggravates mTBI-induced hippocampal pathological changes. HHCY was induced in adult male Sprague-Dawley rats with a high methionine dose. Rats were then subjected to mTBI by controlled cortical impact under sustained HHCY. Blood plasma was assessed for homocysteine levels and brain tissue for markers of oxidative stress, blood-brain barrier integrity, and cell death. Endothelial cell ultrastructure was assessed by Electron Microscopy and working memory performance using the Y maze test. HHCY increased the hippocampal expression of nitrotyrosine in astroglial cells and decreased tight junction protein occludin levels associated with the enlargement of the endothelial cell nucleus. Furthermore, HHCY altered the expression of apoptosis-regulating proteins α-ii spectrin hydrolysis, ERK1/2, and AKT phosphorylation, mirrored by exacerbated mTBI-related hippocampal neuronal loss and working memory deficits. Our findings indicate that HHCY is an epigenetic factor that modulates mTBI pathological progression in the hippocampus and represents a putative therapeutic target for mitigating such physiological stressors that increase severity.
Sections du résumé
Background
UNASSIGNED
Mild traumatic brain injury (mTBI) generally resolves within weeks. However, 15-30% of patients present persistent pathological and neurobehavioral sequelae that negatively affect their quality of life. Hyperhomocysteinemia (HHCY) is a neurotoxic condition derived from homocysteine accumulation above 15 μM. HHCY can occur in diverse stressful situations, including those sustained by U.S. active-duty service members on the battlefield or during routine combat practice. Mild-TBI accounts for more than 80% of all TBI cases, and HHCY exists in 5-7% of the general population. We recently reported that moderate HHCY exacerbates mTBI-induced cortical injury pathophysiology, including increased oxidative stress. Several studies have demonstrated hippocampus vulnerability to oxidative stress and its downstream effects on inflammation and cell death.
Objective
UNASSIGNED
This study aimed to assess the deleterious impact of HHCY on mTBI-associated hippocampal pathological changes. We tested the hypothesis that moderate HHCY aggravates mTBI-induced hippocampal pathological changes.
Methods
UNASSIGNED
HHCY was induced in adult male Sprague-Dawley rats with a high methionine dose. Rats were then subjected to mTBI by controlled cortical impact under sustained HHCY. Blood plasma was assessed for homocysteine levels and brain tissue for markers of oxidative stress, blood-brain barrier integrity, and cell death. Endothelial cell ultrastructure was assessed by Electron Microscopy and working memory performance using the Y maze test.
Results
UNASSIGNED
HHCY increased the hippocampal expression of nitrotyrosine in astroglial cells and decreased tight junction protein occludin levels associated with the enlargement of the endothelial cell nucleus. Furthermore, HHCY altered the expression of apoptosis-regulating proteins α-ii spectrin hydrolysis, ERK1/2, and AKT phosphorylation, mirrored by exacerbated mTBI-related hippocampal neuronal loss and working memory deficits.
Conclusion
UNASSIGNED
Our findings indicate that HHCY is an epigenetic factor that modulates mTBI pathological progression in the hippocampus and represents a putative therapeutic target for mitigating such physiological stressors that increase severity.
Identifiants
pubmed: 36909831
doi: 10.1177/11795735231160025
pii: 10.1177_11795735231160025
pmc: PMC9996738
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11795735231160025Informations de copyright
© The Author(s) 2023.
Déclaration de conflit d'intérêts
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
J Cereb Blood Flow Metab. 2018 Aug;38(8):1312-1326
pubmed: 28685618
Crit Care. 2005 Feb;9(1):66-75
pubmed: 15693986
Cell. 2016 Nov 3;167(4):897-914
pubmed: 27814520
Neuropharmacology. 2014 Oct;85:427-39
pubmed: 24937045
Exp Neurol. 1976 Sep;52(3):447-58
pubmed: 954917
Am J Physiol Heart Circ Physiol. 2005 Dec;289(6):H2649-56
pubmed: 16085680
Int J Crit Illn Inj Sci. 2016 Apr-Jun;6(2):70-3
pubmed: 27308254
J Neurosci. 2000 Sep 15;20(18):6920-6
pubmed: 10995836
J Neurotrauma. 2009 Jun;26(6):925-39
pubmed: 19331514
Brain Res. 2014 Jul 29;1574:105-12
pubmed: 24929209
Handb Clin Neurol. 2015;127:45-66
pubmed: 25702209
Sci Rep. 2017 Sep 7;7(1):10846
pubmed: 28883638
J Neurosci Res. 2002 Dec 1;70(5):694-702
pubmed: 12424737
FASEB J. 2007 Aug;21(10):2400-8
pubmed: 17356006
J Neurotrauma. 2013 Apr 1;30(7):565-79
pubmed: 23151067
Cell Death Dis. 2019 Jul 22;10(8):561
pubmed: 31332165
J Neurotrauma. 2008 Feb;25(2):153-71
pubmed: 18260798
Front Neurol. 2018 Dec 19;9:1113
pubmed: 30619066
Blood. 2006 Jan 15;107(2):591-3
pubmed: 16189268
Pharmacol Res. 2020 Jul;157:104769
pubmed: 32275963
Front Mol Neurosci. 2016 Jan 12;8:87
pubmed: 26793056
J Alzheimers Dis. 2015;43(1):29-35
pubmed: 25061050
J Biol Chem. 2019 Jul 19;294(29):11154-11165
pubmed: 31167782
Front Cell Neurosci. 2013 Jan 28;7:5
pubmed: 23372544
Nat Neurosci. 2018 Feb;21(2):258-269
pubmed: 29335604
Neuropsychiatr Dis Treat. 2009;5:103-16
pubmed: 19557105
Lancet. 1975 Mar 1;1(7905):480-4
pubmed: 46957
J Neurosci. 2006 Nov 22;26(47):12237-41
pubmed: 17122048
J Neurotrauma. 2018 May 15;35(10):1192-1203
pubmed: 29187028
Neurobiol Aging. 2013 May;34(5):1397-411
pubmed: 23273602
Front Immunol. 2018 Apr 06;9:697
pubmed: 29681904
Lancet. 2007 Jan 20;369(9557):208-16
pubmed: 17240287
Med Sci Monit. 2012 Dec;18(12):CR771-776
pubmed: 23241651
Eur Neuropsychopharmacol. 2019 Oct;29(10):1065-1082
pubmed: 31371103
Front Neurol. 2021 Feb 10;12:576366
pubmed: 33643182
Arch Intern Med. 1998 Aug 10-24;158(15):1617-24
pubmed: 9701095
J Comp Neurol. 1999 Apr 19;406(4):449-60
pubmed: 10205022
Mil Med. 2018 Nov 1;183(11-12):e649-e658
pubmed: 30124915
Kidney Med. 2022 Jan 13;4(3):100411
pubmed: 35386598
Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):7109-14
pubmed: 9192700
J Neurosci Res. 2004 Aug 15;77(4):540-51
pubmed: 15264224
Psychol Rev. 1992 Apr;99(2):195-231
pubmed: 1594723
Am J Med Genet C Semin Med Genet. 2011 Feb 15;157C(1):3-32
pubmed: 21308989
Neurosci Biobehav Rev. 2004 Sep;28(5):497-505
pubmed: 15465137
J Neurosci. 2003 May 15;23(10):4117-26
pubmed: 12764099
Lancet Neurol. 2013 Jan;12(1):53-64
pubmed: 23177532
Biosci Biotechnol Biochem. 2006 Oct;70(10):2403-9
pubmed: 17031061
J Neurotrauma. 2015 Aug 15;32(16):1200-9
pubmed: 25594545
J Head Trauma Rehabil. 1999 Dec;14(6):602-15
pubmed: 10671706
J Head Trauma Rehabil. 2008 Mar-Apr;23(2):123-31
pubmed: 18362766
Front Nutr. 2019 Apr 24;6:49
pubmed: 31069230
FEBS Lett. 2006 May 29;580(13):2994-3005
pubmed: 16697371
Nat Rev Neurosci. 2020 Mar;21(3):153-168
pubmed: 32042144
J Neurol Neurosurg Psychiatry. 2018 Nov;89(11):1152-1162
pubmed: 29674479
J Vasc Surg. 2003 Nov;38(5):904-8
pubmed: 14603192
Ann Thorac Surg. 2009 Aug;88(2):543-50
pubmed: 19632410
Arterioscler Thromb Vasc Biol. 2000 Sep;20(9):2032-7
pubmed: 10978245
Exp Neurol. 2017 Mar;289:9-20
pubmed: 27923561
PLoS One. 2022 May 27;17(5):e0269101
pubmed: 35622845
Curr Biol. 2016 Oct 10;26(19):2629-2634
pubmed: 27666968
Cell Mol Neurobiol. 2021 Apr;41(3):487-503
pubmed: 32405706
Cell Mol Neurobiol. 2019 Jul;39(5):687-700
pubmed: 30949917
Phys Med Rehabil Clin N Am. 2011 Nov;22(4):683-700, ix
pubmed: 22050943
Clin Chim Acta. 2018 Jul;482:149-154
pubmed: 29627488
Development. 2014 May;141(10):1983-6
pubmed: 24803647